CT Perfusion Imaging to Predict Vasospasm in Subarachnoid Hemorrhage

Subarachnoid Hemorrhage Clinical Trial

— CT-PIPS  

Official title:

CT Perfusion Imaging to Predict Vasospasm in Subarachnoid Hemorrhage

Clinical Trial Details — Status: Active, not recruiting

Administrative data

• NCT number: NCT02056769
• Other study ID #: CT-PIPS
• Status: Active, not recruiting
• Phase: N/A
• Start date: April 2014
• Est. completion date: February 2024

Study information

• Verified date: February 2023
• Source: Nova Scotia Health Authority
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

Patients with brain hemorrhage resulting from a ruptured aneurysm (SAH) are at risk of developing a condition called vasospasm, one or two weeks after their hemorrhage. This is a major cause of stroke and death following SAH. A special type of CT scan, called CT perfusion, analyzes regional blood flow in the brain. We hypothesize that CT perfusion scans performed on admission and day 6 post-hemorrhage will enable us to predict which patients will go on to develop vasospasm.

Description:

Rupture of a brain aneurysm results in a type of bleeding into the brain called subarachnoid hemorrhage (SAH). This is a substantial cause of morbidity and mortality world-wide: even with the best possible care, up to half of patients die and many are left disabled. Sometimes this is because the immediate brain damage from the bleed is very severe. However, many patients who seem to be doing well at first go on to develop something called "vasospasm": narrowing of large arteries in the brain. This results in the brain not getting enough blood, and the patient can suffer a stroke as a result. The lack of blood to the brain is called delayed cerebral ischemia (DCI), and is the major secondary cause of stroke and death in patients who survived the initial aneurysm rupture. Vasospasm can be seen on angiograms (blood vessel imaging) in about two-thirds of SAH patients, and causes neurological symptoms of DCI in half of those patients. It usually develops about a week or so after SAH. Early diagnosis and treatment of cerebral vasospasm and delayed cerebral ischemia (DCI) reduces morbidity and mortality in SAH patients. CT perfusion imaging is able to identify areas of reduced cerebral blood flow that are at risk of DCI and stroke. This technique is able to measure cerebral blood flow and blood volume (CBF, CBV), and calculates two other measures of cerebral perfusion: time to peak intensity (TTP) and mean transit time (MTT). Taken together, these provide information about the amount of blood the brain is receiving and whether the brain is compensating for any reduction in flow. This is helpful because seeing vasospasm on imaging is not enough to predict brain ischemia and stroke; the additional physiological information provided by the perfusion assessment strengthens the diagnosis of DCI. Early evidence suggests that CT perfusion is a fast, accurate, inexpensive and non-invasive method of brain imaging to identify patients with DCI after SAH, and guide appropriate therapy. If we were able to successfully predict which patients are at high risk of DCI and/or stroke, we could intervene early. This could improve patient outcomes, while potentially allowing better use of limited intensive care and nursing resources. Other studies have shown that patients with DCI had altered perfusion prior to developing clinical symptoms, but we do not know whether we can use CT perfusion to predict patients at risk, or which CT perfusion measurements (e.g., CBF or TTP) are most useful. The radiation risk associated with CT perfusion imaging is negligible, due to advances in CT technology which allow for routine simultaneous CT perfusion and CT angiogram (CTA) without a significant increase in radiation dose over conventional head CT-CTA alone. Judicious use of CT perfusion, through a structured algorithm that includes routine perfusion scans at admission and during the peak risk period for vasospasm, may actually decrease cumulative radiation dose for patients with SAH, by ruling out perfusion deficit and brain ischemia as a cause of decreased neurological function and limiting repeated angiograms.

Recruitment information / eligibility

• Status: Active, not recruiting
• Enrollment: 41
• Est. completion date: February 2024
• Est. primary completion date: June 2018
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years to 75 Years

Eligibility

Inclusion Criteria:

• Patient is between 18 and 75 years of age (inclusive).
• Patient has a documented aneurysmal SAH.
• Patient or next of kin or person with appropriate power of attorney has provided written informed consent.
• Patient is willing and available for study follow-up visits.
• Patient has not been previously entered into this study.

Exclusion Criteria:

• Inability to obtain informed written consent.
• Patient is < 18 or > 75 years old.
• Patient is not expected to survive >24 hours (e.g. those presenting with loss of brain stem reflexes, or patients transferred to the Halifax Infirmary ICU for consideration of organ donation rather than active treatment)
• Patient history indicates high risk of non-compliance (e.g., substance abuse, psychosocial issues, etc.)
• Patient is currently breast feeding, or pregnant
• Patient is currently enrolled in another clinical study (device or drug).

Related Conditions & MeSH terms

• Brain Ischemia
• Cerebral Infarction
• Cerebral Vasospasm
• CT Perfusion
• Delayed Cerebral Ischemia
• Hemorrhage
• Ischemia
• Subarachnoid Hemorrhage
• Vasospasm, Intracranial

Intervention

Radiation:
• CT Perfusion
Quantitative CT Perfusion imaging

Locations

Country	Name	City	State
Canada	Halifax Infirmary, Capital District Health Authority	Halifax	Nova Scotia

Sponsors (1)

Lead Sponsor	Collaborator
Nova Scotia Health Authority

Country where clinical trial is conducted

Canada, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Other	Delayed Cerebral Ischemia	Delayed cerebral ischemia is defined using a consensus recently agreed upon by an international panel of experts: namely, 1) stroke seen on CT or MRI scan, or proven at autopsy (not including stroke related to the aneurysm treatment), or 2) clinical deterioration presumed to be caused by DCI after other causes are excluded.	30 days post-SAH
Primary	CBF Admit	Cerebral blood flow as measured on CT perfusion study on admission	Baseline
Primary	CBV Admit	Cerebral blood volume as measured on CT perfusion study on admission	Baseline
Primary	MTT Admit	Mean transit time as measured on CT perfusion study on admission	Baseline
Primary	TTP Admit	Time to peak as measured on CT perfusion study on admission	Baseline
Primary	CBF day 6	Cerebral blood flow as measured on CT perfusion study on day 6 following subarachnoid hemorrhage	Day 6 post-SAH
Primary	CBV day 6	Cerebral blood volume as measured on CT perfusion study on day 6 following subarachnoid hemorrhage	Day 6 post-SAH
Primary	MTT day 6	Mean transit time as measured on CT perfusion study on day 6 following subarachnoid hemorrhage	Day 6 post-SAH
Primary	TTP day 6	Time to peak as measured on CT perfusion study on day 6 following subarachnoid hemorrhage	Day 6 post-SAH
Secondary	Radiation Dose	Total cumulative radiation dose from cranial imaging (CT Head, CT angiogram, CT perfusion, catheter angiography, endovascular coiling) during the initial hospital admission for SAH, up to 30 days post-SAH.	30 days post-SAH